Brief: Cullinan Therapeutics Q2 Operating Expenses USD 75.798 Million

Cullinan Therapeutics

07/08/2025 12:00

Overview

Cullinan reports Q2 net loss of $70.1 mln, up from $42.0 mln last year

Operating expenses rise to $75.8 mln, driven by R&D costs

Company maintains $510.9 mln cash position, runway into 2028

Outlook

Cullinan expects NDA submission for zipalertinib by end of 2025

Company plans to complete REZILIENT3 enrollment in 1H 2026

Cullinan to share CLN-049 clinical data in Q4 2025

Company's cash runway expected to last into 2028

Result Drivers

CLN-978 PROGRAM - Active enrollment in Phase 1 studies for SLE, RA, and Sjögren’s disease

R&D - Expenses were $61.0 million for the second quarter of 2025, compared to $36.3 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$70.06 mln
Q2 Cash & Investments
$510.90 mln
Q2 Operating Expenses
$75.80 mln
Q2 Operating Income
-$75.80 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Cullinan Therapeutics Inc is $30.00, about 73.7% above its August 6 closing price of $7.88

Press Release: ID:nGNX4jMPBm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)